Shareholder’s Equity (Deficit) |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Equity [Abstract] | |
| Shareholder’s Equity (Deficit) | Note 7 — Shareholder’s Equity (Deficit)
Ordinary shares — The Company is authorized to issue up to ordinary shares, par value $ per share. Holders of ordinary shares are entitled to one vote for each share held on all matters to be voted on by shareholders, except as required by law. On September 25, 2025, the Sponsor subscribed for ordinary shares for an aggregate purchase price of $25,000. On January 9, 2026, the Company and the Sponsor entered into the First Amendment to the Subscription Agreement, pursuant to which the number of ordinary shares subscribed for by the Sponsor was increased to ordinary shares for the same aggregate purchase price of $25,000.
In connection with the IPO and full exercise of the underwriters’ over-allotment option, the Company issued private placement shares as part of the private placement units and 230,000 representative shares to the underwriters. As of June 30, 2026, the Company had non-redeemable ordinary shares issued and outstanding, excluding ordinary shares subject to possible redemption. As of December 31, 2025, the Company had ordinary shares issued and outstanding.
Rights — Each public unit and private placement unit includes one right. Each right entitles the holder to receive one-fourth (1/4) of one ordinary share upon consummation of a Business Combination. No fractional shares will be issued upon conversion of the rights. No additional consideration will be required to be paid by a holder of rights in order to receive ordinary shares upon consummation of a Business Combination, as the consideration related thereto was included in the unit purchase price.
As of June 30, 2026, there were 11,727,500 rights outstanding, consisting of 11,500,000 public rights and 227,500 private rights. As of December 31, 2025, there were no rights outstanding.
If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates, holders of rights will not receive any funds from the Trust Account with respect to such rights, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such rights. Accordingly, the rights may expire worthless.
|